Denise Morini - Publications

Personalized Venetoclax Dose Adjustment in Unfit Acute Myeloid Leukemia Patients: A Real-Life Case Series Study.

Journal: Journal of personalized medicine

Published: February 25, 2026

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies.

Journal: International journal of laboratory hematology

Published: September 10, 2025

Multiple myeloma patients treated with lenalidomide-based regimens frequently experience delayed peripheral blood stem cell collection: A controlled real-life study.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: July 13, 2025

Prolonged Hematogone Expansion Is Associated with Better Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Journal: Hematology reports

Published: July 08, 2025

Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.

Journal: Annals of hematology

Published: April 24, 2025

Circulating T Regulatory Cells Are Persistently Reduced in Non-Severe Acquired Aplastic Anemia.

Journal: Current medical science

Published: March 03, 2025

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Journal: European journal of haematology

Published: July 23, 2024

Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience.

Journal: Hematology reports

Published: December 24, 2023

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.

Journal: Cancer medicine

Published: November 11, 2023

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.

Journal: Cancer reports (Hoboken, N.J.)

Published: October 28, 2023

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.

Journal: Targeted oncology

Published: September 08, 2023

Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.

Journal: European journal of haematology

Published: May 21, 2023